Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer
“During her tenure, Christina has served as a trusted advisor to our entire executive team, and she has played an integral role in shaping Flexion’s corporate priorities and advancing the development of our portfolio,” said
Ms. Willwerth has 25 years of experience in pharmaceutical development. Prior to joining Flexion, she served as Vice President, Product Development at Viacell and was a member of the company’s executive management team. Previously she served as Senior Director, Product Development at The
This release contains forward-looking statements that are based on the current expectations and beliefs of Flexion. Statements in this release regarding matters that are not historical facts, including, but not limited to, statements relating to the future expected benefits of Flexion's appointment of Ms. Willwerth to Chief Strategy Officer, are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, whether we are able to retain key employees including Ms. Willwerth; our ability to meet our goals; and other risks and uncertainties described in our filings with the
Manager, Corporate Communications
Source: Flexion Therapeutics, Inc.